|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum.
|
30994537 |
2019 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RNA sequencing and Sanger sequencing identified PIK3CA (p.E545K/p.H1047R) and/or HRAS (p.Q61R) hotspot mutations in 6 of 8 (75%) apocrine carcinomas.
|
29443014 |
2018 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Combined Harvey rat sarcoma viral oncogene homolog/phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit α (HRAS/PIK3CA) mutations were observed predominantly in de novo carcinomas (5 of 8 vs 2 of 31 tumors; P = .035).
|
27379604 |
2016 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
HRAS mutations accounted for more than 90% of RAS mutations, occurring especially in epithelial-myoepithelial carcinomas and salivary duct carcinomas.
|
26053092 |
2015 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
|
25795707 |
2015 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin.
|
23380875 |
2013 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Paradoxically, reports have suggested a greater frequency of Ki-ras gene mutation in these lesions than in more complex lesions such as benign colonic adenomas and carcinomas.
|
21443421 |
2011 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Activating point mutations of genes of the RAS family (KRAS, HRAS and NRAS genes) are frequently found in carcinomas, but their prevalence in sarcomas varies considerably among ethnic groups.
|
20150643 |
2010 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
RAS mutations in codon 61 were by far the most common genetic alteration in poorly differentiated carcinomas (23% of cases), with all mutation in NRAS except one in the HRAS gene.
|
19837916 |
2009 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the advantages of rat models characterized by larger organ size, abundant information regarding preneoplasias and virus-free constitution, we have concentrated on the generation of transgenic rats bearing copies of the human c-Ha-ras proto-oncogene and shown the Hras128 strain to be extremely sensitive to the induction of mammary carcinomas, and to a lesser extent, lesions in the urinary bladder, esophagus and skin.
|
15958052 |
2005 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore it is of interest to investigate whether expression of human c-Ha-ras affects the androgen-dependence of prostate carcinomas developing in the PB/SV40T Tg rat.
|
14662018 |
2003 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The findings for the Ki-ras gene in 42 paired carcinomas and synchronous metastases were identical, regardless of whether or not the carcinoma and its companion adenoma had identical Ki-ras findings.
|
12782759 |
2003 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
K14/IL-1 alpha mice crossed with the highly sensitive TG.AC mice, constitutively expressing mutant Ha-Ras, also failed to develop papillomas or carcinomas.
|
12759452 |
2003 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among 74 KRAS2-mutant carcinomas, no BRAF mutations were identified.
|
14507635 |
2003 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
On the other hand, Ki-ras gene mutations were inversely correlated with MSI, which was found in diploid carcinomas only.
|
11754204 |
2001 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
KRAS2 mutations were seen in 5/51 (10%) MSI-positive carcinomas.
|
11746970 |
2001 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation.
|
10767358 |
2000 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Using a transgenic mouse model expressing the E2F1 gene under the control of a keratin 5 (K5) promoter, we previously demonstrated that increased E2F1 activity can promote tumorigenesis by cooperating with either a v-Ha-ras transgene to induce benign skin papillomas or p53 deficiency to induce spontaneous skin carcinomas.
|
10454586 |
1999 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Analysis of HK1.fos/alpha papillomas and carcinomas revealed that the endogenous c-Ha-ras gene possessed mutations at codons 12, 13, and 61 at the papilloma stage, but no mutations of the p53 tumor suppressor gene were detected.
|
10569807 |
1999 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, these studies also suggest for the first time that the distinct and likely cooperative biological functions of the Ki-ras-encoded Ki-Ras 4A and Ki-Ras 4B proteins may help explain why constitutively activating mutations of Ki-ras, but not N-ras or Ha-ras, are frequently detected in human carcinomas.
|
10358073 |
1999 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The farnesyltransferase inhibitor L-744,832 selectively blocks the transformed phenotype of cultured cells expressing a mutated H-ras gene and induces dramatic regression of mammary and salivary carcinomas in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic mice.
|
9418856 |
1998 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our results obtained on a large series confirm the frequent occurrence of Ha-ras codon 12 gene mutations both in adenomas and in carcinomas.
|
9724079 |
1998 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our method of topographic genotyping of human colonic carcinomas has shown a correlation between K-ras-2 and p53 mutations and stage at diagnosis as well as long-term survival.
|
9142390 |
1997 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The mutational frequency of the Ki-ras gene in the present series of small intestinal carcinomas was similar, while that of the p53 gene was slightly lower than the reported frequencies for colorectal carcinomas.
|
9033644 |
1997 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations of K-RAS-2 gene and tumour suppressor genes have been found in both colorectal adenomas and carcinomas.
|
9361177 |
1997 |